Clinical trials: Bleeding Tendency; Due to Coagulation Defect
- Condition Bleeding Tendency; Due to Coagulation Defect
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Hemophilia A
Study to Learn More About the Safety of Drug Jivi Over a Long Period of Time in Previously Treated Patients With Hemophilia A (Bleeding Disorder Resulting From a Lack of FVIII) Who Are Receiving Jivi Regularly at Their Treating Doctors to Prevent Bleeding
In this observational study researchers want to learn more about the safety of drug Jivi over a long period of time. Jivi (generic name: Damoctocog alfa pegol) is an approved blood clotting Factor VIII (FVIII) medication for the…
- Trial name
- HA-SAFE (NCT04461639)
- Testing
- Damoctocog alfa pegol (Jivi, BAY94-9027)
- Where
- 6 sites in Austria, Germany and 4 more
- Volunteers
- 62 people
- Sponsor
- Bayer